{"denoms":[{"counts":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"30"},{"groupId":"BG006","value":"42"},{"groupId":"BG007","value":"104"}],"units":"Participants"}],"groups":[{"description":"Participants were administered with 7 full intravenous (IV) infusion of 0.005, 0.05, 0.1, 0.5, 1 and 2 milligram per kilogram body weight (mg/kg) daratumumab once weekly, along with this participants also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.","id":"BG000","title":"Part 1 - <4 mg/kg"},{"description":"Participants were administered with 7 full IV infusion of 4 mg/kg daratumumab once weekly, along with this participants also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.","id":"BG001","title":"Part 1 - 4 mg/kg"},{"description":"Participants were administered with 7 full IV infusion of 8 mg/kg daratumumab once weekly, along with this participants also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.","id":"BG002","title":"Part 1 - 8 mg/kg"},{"description":"Participants were administered with 7 full IV infusion of 16 mg/kg daratumumab once weekly, along with this participants also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.","id":"BG003","title":"Part 1 - 16 mg/kg"},{"description":"Participants were administered with 7 full IV infusion of 24 mg/kg daratumumab once weekly, along with this participants also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.","id":"BG004","title":"Part 1 - 24 mg/kg"},{"description":"Participants were administered with 8 full IV infusions of 8 mg/kg daratumumab once weekly for 8 weeks, then every 2 weeks (q2w) for 16 weeks, then every 4 weeks (q4w) until the participant experienced disease progression or unmanageable toxicity whichever came first, along with this participants also received methylprednisolone 100 mg IV before treatment and 20-25 mg methylprednisolone orally for 2 days after all full infusions.","id":"BG005","title":"Part 2 - 8 mg/kg"},{"description":"Participants were administered with 8 full IV infusions of 16 mg/kg daratumumab once weekly for 7 weeks, then every 2 weeks (q2w) for 14 weeks, then every 4 weeks (q4w) until the participant experienced disease progression or unmanageable toxicity whichever came first, along with this participants also received methylprednisolone 100 mg IV before treatment and 20-25 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.","id":"BG006","title":"Part 2 - 16 mg/kg"},{"description":"Total of all reporting groups","id":"BG007","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"21"},{"groupId":"BG006","value":"22"},{"groupId":"BG007","value":"63"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"20"},{"groupId":"BG007","value":"41"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.24","value":"61.8"},{"groupId":"BG001","spread":"2","value":"64"},{"groupId":"BG002","spread":"6.11","value":"61.3"},{"groupId":"BG003","spread":"1.73","value":"53"},{"groupId":"BG004","spread":"9.54","value":"59"},{"groupId":"BG005","spread":"10.05","value":"58.6"},{"groupId":"BG006","spread":"8.27","value":"63.8"},{"groupId":"BG007","spread":"9","value":"61.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"15"},{"groupId":"BG007","value":"33"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"21"},{"groupId":"BG006","value":"27"},{"groupId":"BG007","value":"71"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"9"},{"groupId":"BG007","value":"30"}]}],"title":"Denmark"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"14"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"32"}]}],"title":"Netherlands"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"11"},{"groupId":"BG007","value":"22"}]}],"title":"Sweden"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"14"},{"groupId":"BG007","value":"20"}]}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"16"},{"groupId":"BG007","value":"26"}],"title":"<= 3 Lines"},{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"24"},{"groupId":"BG006","value":"26"},{"groupId":"BG007","value":"78"}],"title":"> 3 Lines"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"No. of Prior Lines of Therapy","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"19"},{"groupId":"BG006","value":"27"},{"groupId":"BG007","value":"54"}],"title":"Both a PI and IMiD"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"6"}],"title":"PI only"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"12"}],"title":"IMiD only"},{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"32"}],"title":"None"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Refractory to proteasome inhibitor (PI)/immunomodulatory agent (IMiD)","unitOfMeasure":"Participants"}]}